ARDX
Price
$6.89
Change
-$0.15 (-2.13%)
Updated
Jan 14 closing price
Capitalization
1.67B
55 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$7.64
Change
-$0.02 (-0.26%)
Updated
Jan 14 closing price
Capitalization
197.63M
Intraday BUY SELL Signals
Interact to see
Advertisement

ARDX vs RNAC

Header iconARDX vs RNAC Comparison
Open Charts ARDX vs RNACBanner chart's image
Ardelyx
Price$6.89
Change-$0.15 (-2.13%)
Volume$3.28M
Capitalization1.67B
Cartesian Therapeutics
Price$7.64
Change-$0.02 (-0.26%)
Volume$96.44K
Capitalization197.63M
ARDX vs RNAC Comparison Chart in %
View a ticker or compare two or three
VS
ARDX vs. RNAC commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Hold and RNAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ARDX: $6.89 vs. RNAC: $7.64)
Brand notoriety: ARDX and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 83% vs. RNAC: 51%
Market capitalization -- ARDX: $1.67B vs. RNAC: $197.63M
ARDX [@Biotechnology] is valued at $1.67B. RNAC’s [@Biotechnology] market capitalization is $197.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 6 bullish TA indicator(s).

  • ARDX’s TA Score: 5 bullish, 4 bearish.
  • RNAC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than ARDX.

Price Growth

ARDX (@Biotechnology) experienced а +18.18% price change this week, while RNAC (@Biotechnology) price change was -1.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

ARDX is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($1.67B) has a higher market cap than RNAC($198M). ARDX YTD gains are higher at: 18.182 vs. RNAC (5.964). ARDX has higher annual earnings (EBITDA): -26.22M vs. RNAC (-121.9M). ARDX has more cash in the bank: 243M vs. RNAC (143M). RNAC has less debt than ARDX: RNAC (12.6M) vs ARDX (208M). ARDX has higher revenues than RNAC: ARDX (398M) vs RNAC (1.09M).
ARDXRNACARDX / RNAC
Capitalization1.67B198M844%
EBITDA-26.22M-121.9M22%
Gain YTD18.1825.964305%
P/E RatioN/A1.98-
Revenue398M1.09M36,480%
Total Cash243M143M170%
Total Debt208M12.6M1,651%
FUNDAMENTALS RATINGS
ARDX vs RNAC: Fundamental Ratings
ARDX
RNAC
OUTLOOK RATING
1..100
2213
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3887
P/E GROWTH RATING
1..100
4744
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (99) in the Biotechnology industry is in the same range as ARDX (100). This means that RNAC’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as RNAC (100). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as RNAC (100). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for RNAC (87). This means that ARDX’s stock grew somewhat faster than RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (44) in the Biotechnology industry is in the same range as ARDX (47). This means that RNAC’s stock grew similarly to ARDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXRNAC
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 18 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signal:
Gain/Loss:
RNAC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMJX5.990.04
+0.67%
Invesco SteelPath MLP Alpha Plus R
VMCCX50.820.15
+0.30%
Virtus KAR Mid-Cap Core C
FIDKX59.67N/A
N/A
Fidelity International Discovery K
IICAX11.64-0.01
-0.09%
AMF Large Cap Equity AMF
NLCCX28.79-0.40
-1.37%
Voya Large-Cap Growth C

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-2.13%
VCYT - ARDX
45%
Loosely correlated
-1.39%
PCVX - ARDX
35%
Loosely correlated
+5.41%
RNAC - ARDX
35%
Loosely correlated
-0.26%
MNOV - ARDX
32%
Poorly correlated
-0.69%
CLRB - ARDX
31%
Poorly correlated
-7.30%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-0.26%
TAOX - RNAC
91%
Closely correlated
+9.19%
ALLR - RNAC
86%
Closely correlated
N/A
NRXP - RNAC
86%
Closely correlated
+0.94%
PALI - RNAC
81%
Closely correlated
+3.17%
VIR - RNAC
45%
Loosely correlated
+8.08%
More